AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India, to import Benralizumab solution for injection in pre-filled syringe for sale and distribution. According to reports from Business Standard, the approval is for an additional indication of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra). However, the stock declined 1.73% on Thursday's trading session, reflecting mixed market sentiment despite the regulatory milestone.
The drug is now indicated for the treatment of patients aged 12 years and above with hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause. As reported by Business Standard, the receipt of this permission paves the way for the marketing of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra) in India for the specified additional indication, subject to receipt of related statutory approvals, if any.
According to Business Standard, AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.
The company's standalone net profit declined 22.95% to ₹44.88 crore in the quarter ended March 2026 as against ₹58.25 crore during the previous quarter ended March 2025. However, sales rose 20.42% to ₹578.61 crore in the quarter ended March 2026 as against ₹480.48 crore during the previous quarter ended March 2025. As reported by Business Standard, the counter slipped 1.77% to ₹8,092 on the BSE.
